Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.58)...
Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of commercial product, and up ...
All 172 patients have now entered the 12-month follow-up phaseTrial involves larger surface areas, building on the approval in ...
Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026Company plans FDA discussion in ...
Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.42)...
